Correction to: Structure and function of therapeutic antibodies approved by the US FDA in 2024 [0.03%]
美国FDA于2024年批准的治疗性抗体的结构和功能的更正
[This corrects the article DOI: 10.1093/abt/tbaf014.]. © The Author(s) 2025. Published by Oxford University Press on behalf of the Chinese Antibody Soci...
Published Erratum
Antibody therapeutics. 2025 Aug 17;8(3):238. DOI:10.1093/abt/tbaf015 2025
Matching placebo development for injectable biologics-a practical tutorial [0.03%]
匹配安慰剂生物制品注射液的开发实践教程
Lun Xin,Zhe Zhang,Kushan Shah et al.
Lun Xin et al.
Background: In drug development, placebo-controlled trials are vital for assessing treatment efficacy. Developing a suitable placebo for injectable biologics presents unique challenges, particularly in matching the physic...
Bypassing the immunosuppressive effects of CA125/MUC16 via re-engineered rituximab (NAV-006) to improve its antitumor activity in vivo [0.03%]
通过改造的利妥昔单抗(NAV-006)绕过CA125/MUC16免疫抑制效应以提高其体内抗肿瘤活性
Luigi Grasso,Bradford J Kline,Nicholas C Nicolaides
Luigi Grasso
The monoclonal antibody rituximab functions through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) and is used to treat non-Hodgkin's lymphoma. Elevated serum CA125/MUC16 levels, present in some ...
A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy [0.03%]
一种新型PD-L1/VEGF双特异性抗体CVL006用于癌症治疗优于AK112
Chunyan Wang,Hao Huang,Zeng Song et al.
Chunyan Wang et al.
Background: Preclinical and clinical studies highlight the enhanced anticancer efficacy of combining anti-VEGF/VEGFR drugs with immune checkpoint inhibitors (ICIs). PD-L1/VEGF bispecific antibodies outperform monotherapy ...
Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody-drug conjugate [0.03%]
新型AXL特异性条件激活生物药物抗体偶联物mecbotamab vedotin（BA3011）的药代动力学/药效学引导的概念验证研究
Hwai Wen Chang,Jing Wang,Haizhen Liu et al.
Hwai Wen Chang et al.
Background: AXL, a tyrosine kinase receptor, is over-expressed in many solid and hematologic cancers, promoting progression and poor clinical outcomes. It also contributes to resistance against chemotherapeutic agents, es...
Qirui Fan,Hu Chen,Guoguang Wei et al.
Qirui Fan et al.
Antibody-drug conjugates (ADCs) have gained significant attention in biotherapeutics after several years of steady development. Among the multiple factors influencing ADC design, the conjugation method is one of the most critical parameters...
Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors [0.03%]
抗体偶联药物非临床及临床毒性概览及相关影响因素
Yumei Cheng,Jing Lu,Chonghao Zhang et al.
Yumei Cheng et al.
An antibody-drug conjugate (ADC), consisting of an antibody, a chemical linker, and a payload, can selectively deliver a highly cytotoxic payload to cancer cells and minimize the systemic toxicity of the payload by harnessing the selectivit...
A systematic review of the avian antibody (IgY) therapeutic effects on human bacterial infections over the decade [0.03%]
过去十年禽类抗体(IgY)治疗人类细菌感染的系统评价
Zahra Esmaeili,Sara Kamal Shahsavar,Kiarash Ghazvini
Zahra Esmaeili
The overuse of antibiotics worldwide, especially during the Coronavirus pandemic, has raised concerns about the rise of antibiotic resistance and its side effects. Immunoglobulin Y, a natural protein that specifically targets foreign antige...
Fundamental properties and principal areas of focus in antibody-drug conjugates formulation development [0.03%]
抗体药物偶联物制剂开发的基本属性和主要研究领域
Lili Wen,Yuanyuan Zhang,Chenxi Sun et al.
Lili Wen et al.
Antibody-drug conjugates (ADCs) have emerged as a rapidly expanding class of therapeutics driven by their superior specificity and clinical efficacy. 14 out of 16 commercially approved ADCs are formulated as lyophilized forms because ADC is...
Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality [0.03%]
抗体治疗中的FCγ受体多态性及其对提高产品质量的生物检测试验开发的影响
Julianne D Twomey,Sasha George,Baolin Zhang
Julianne D Twomey
The effectiveness of therapeutic antibodies is often associated with their Fc-mediated effector functions, such as antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. These functions rely on interactions b...